A message from Goodway Technologies
Optimizing Maintenance Strategies in Power Generation: Embracing Predictive and Preventive Approaches
SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.
Nuclear's future discussed at MURR expansion
ANS Executive Director/CEO Craig Piercy recently spoke on nuclear power’s potential for answering today’s energy demands as part of the Distinguished Lecture Series at the University of...
Framatome, IBA to develop At-211 production network in Europe and U.S.
French nuclear energy company Framatome and Belgian particle accelerator technology company Ion Beam Applications (IBA) have signed a memorandum of understanding to advance the...
Framatome to produce Lu-177 at Romania’s Cernavoda
Framatome and SN Nuclearelectrica, a partially state-owned Romanian nuclear energy company, have entered into a long-term cooperation agreement to produce the medical isotope lutetium-177 at...
TerraPower reaches market-scale production of Ac-225
TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the...
QSA Global, Niowave to collaborate on Ac-225 production using Ra-226
QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification...
ANS Annual Conference special plenary: Our friends the isotopes
“What can the atom do for you, other than produce electricity from nuclear reactors?” That was the question asked and answered during an ANS Annual Conference special plenary session on...
Zeno looks to SHINE for Sr-90 to fuel its radioisotope power systems
Wisconsin-based fusion technology company SHINE Technologies announced today the signing of a memorandum of understanding with Zeno Power to develop a nuclear materials supply chain for its...
Orano Med inaugurates Pb-212 production facility in Indiana
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near...
Oklo’s Diané presents at Community of Practice
The American Nuclear Society’s Risk-informed, Performance-based Principles and Policy Committee (RP3C) held another Community of Practice (CoP) on April 26. For this event, the committee...
Framatome, KHNP to investigate producing Lu-177 in South Korea
Framatome and Korea Hydro & Nuclear Power (KHNP) have announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177 at...
